GILD Scores FDA Win for HDV Drug, CHMP Backs Trodelvy
Gilead wins FDA approval for Hepcludex, the first U.S. therapy for chronic HDV, while Trodelvy advances in Europe for TNBC.
GILD - Gilead Sciences, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$161.76
DETAILS
HIGH:
$180.00
LOW:
$133.00
MEDIAN:
$165.00
CONSENSUS:
$161.76
UPSIDE:
20.39%
Stock News
Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference
Gilead Sciences NASDAQ: GILD Chief Medical Officer Dietmar Berger outlined several upcoming clinical and regulatory priorities across oncology, inflammation and HIV during a discussion with RBC Capital Markets senior biotech analyst Brian Abrahams.
US FDA approves Gilead's drug for deadly liver infection
The U.S. Food and Drug Administration said on Friday it approved Gilead Sciences' drug for a rare and deadly liver infection that previously had no approved treatment options.
FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Hepcludex® (bulevirtide-gmod) 8.5 mg for the treatment of adults living with chronic hepatitis delta virus (HDV) infection, making it the first and only approved treatment for HDV in the United States. The FDA granted accelerated approval to Hepcludex based on reductions in HDV RNA and normalization of alanine aminotrans.
FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Hepcludex (bulevir
Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorization of Trodelvy® (sacituzumab govitecan-hziy) as a monotherapy for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for met.
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite's Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that together with Kite, a Gilead company, it will present more than 25 abstracts, including six oral presentations, at the 2026 ASCO Annual Meeting (May 29 – June 2) and the 2026 EHA Congress (June 11 – 14). These presentations underscore the increasing diversity of Gilead's oncology portfolio and pipeline reflecting a growing body of evidence across both solid tumors and hematolog.
Why Gilead Sciences Is Now A Hold (Rating Upgrade)
Gilead Sciences, Inc. once again demonstrated strong performance of Trodelvy, Livdelzi, and Yeztugo. This "trio" generated $701 million in revenue for Gilead in Q1, up 110.5% quarter-on-quarter. However, Gilead's cell therapy franchise is once again struggling, with sales of Yescarta and Tecartus falling 12.3% YoY.
Forget Moderna: This Biotech Juggernaut Is a Way Better Buy Right Now
Moderna (NASDAQ:MRNA | MRNA Price Prediction) is back in the headlines after ripping 63.17% higher year to date on a surprise Q1 revenue triple and renewed pipeline excitement.
Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Tubulis GmbH, a private Germany-based, clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs). The acquisition brings Gilead next-generation ADC assets and a platform designed to maximize patient benefit through more selective delivery of diverse payloads to tumors. Tubulis' technologies enable th.
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease
Gilead Sciences, Inc. (Nasdaq: GILD) today announced a renewed five-year collaboration with the World Health Organization (WHO), committing funding, strategic
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a renewed five-year collaboration with the World Health Organization (WHO), committing funding, strategic support and product donations to accelerate progress toward eliminating visceral leishmaniasis (VL), also known as kala-azar. VL, the second deadliest parasitic disease after malaria, is a sandfly-borne illness that attacks internal organs and can be fatal if untreated. The expanded agreement aims to.
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Gilead Sciences, Inc. (GILD) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Gilead Sciences, Inc. (GILD) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline
Gilead Sciences NASDAQ: GILD Chief Commercial Officer and Head of Corporate Affairs Johanna Mercier said the company is leaning on its HIV business while continuing to build out oncology and inflammation through recent acquisitions and pipeline development.
Gilead Prices $3 Billion of Senior Unsecured Notes
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $3 billion, in an underwritten, registered public offering, consisting of $500 million of 4.250% senior notes maturing in 2028, $1 billion of 4.400% senior notes maturing in 2029, $1 billion of 4.600% senior notes maturi.
Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Gilead's Transition Into A Long-Duration Biotech Platform
Gilead Sciences is executing a successful transition from a mature antiviral company to a diversified therapeutic platform, driving a 34% stock rally. HIV revenue grew 10% YoY, with Yeztugo's explosive PrEP growth and raised guidance to $1B, signaling a durable, long-acting franchise. Oncology is gaining strategic coherence, led by Trodelvy's 37% YoY growth and platform expansion via acquisitions in ADCs, CAR-T, and autoimmune.
Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present findings from 29 abstracts, including late-breaking presentations at the European Association for the Study of the Liver (EASL) Congress, May 27-30, 2026, Barcelona. These presentations advance understanding of primary biliary cholangitis (PBC) and viral hepatitis. In PBC, Gilead will present randomized and long-term study data for Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union. Analyses fr.
Gilead Sciences, Inc. (GILD) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Gilead Sciences, Inc. (GILD) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Price Targets
Gilead upgraded to Buy at Maxim on approaching growth drivers, valuation
$165.00
(was $130.55)
Michael Okunewitch
·
Maxim Group
Gilead price target lowered to $168 from $175 at Morgan Stanley
$168.00
(was $131.33)
Morgan Stanley
Gilead price target raised to $157 from $155 at Truist
$157.00
(was $132.03)
Truist Financial
Gilead price target raised to $175 from $171 at Morgan Stanley
$175.00
(was $140.34)
Morgan Stanley
Gilead price target raised to $155 from $152 at Truist
$155.00
(was $141.54)
Gregory Renza
·
Truist Financial
Jefferies Starts Gilead Sciences (GILD) at Buy
$180.00
(was $146.94)
Akash Tewari
·
Jefferies
Gilead initiated with an Equal Weight at Barclays
$155.00
(was $151.12)
Barclays
Gilead price target raised to $170 from $140 at Mizuho
$170.00
(was $152.74)
Mizuho Securities
Gilead price target raised to $175 from $155 at UBS
$175.00
(was $155.27)
UBS
Gilead price target raised to $177 from $140 at Scotiabank
$177.00
(was $155.29)
Louise Chen
·
Scotiabank
Gilead Sciences (GILD) PT Raised to $160 at Bernstein SocGen Group
$160.00
(was $155.45)
Courtney Breen
·
Bernstein
Gilead price target raised to $171 from $150 at Morgan Stanley
$171.00
(was $155.72)
Morgan Stanley
Gilead Sciences (GILD) PT Raised to $162 at BofA Securities
$162.00
(was $155.87)
Truist Financial
Gilead price target raised to $152 from $145 at Truist
$152.00
(was $154.69)
Truist Financial
Gilead price target raised to $165 from $128 at Oppenheimer
$165.00
(was $153.46)
Oppenheimer
Gilead price target raised to $155 from $135 at Cantor Fitzgerald
$155.00
(was $147.23)
Cantor Fitzgerald
Gilead Sciences (GILD) PT Raised to $170 at Needham
$170.00
(was $154.09)
Joseph Stringer
·
Needham
Gilead price target raised to $145 from $108 at Baird
$145.00
(was $153.89)
Robert W. Baird
Gilead price target raised to $160 from $150 at BMO Capital
$160.00
(was $147.23)
Evan Seigerman
·
BMO Capital
Gilead price target raised to $165 from $150 at Wells Fargo
$165.00
(was $147.23)
Mohit Bansal
·
Wells Fargo